Columbia Laboratories to Present at Roth Capital Partners
Equity Conference in NYC on September 6, 2006
LIVINGSTON, NJ— August 7, 2006—Columbia Laboratories, Inc. (NASDAQ: CBRX) announced today that its president and chief executive officer, Robert S. Mills, will present at the upcoming Roth Capital Partners 2006 New York Conference.
| Date: | Wednesday, September 6, 2006 |
| Time: | 12:30 PM Eastern Time |
| Venue: | The Westin Times Square Hotel, New York City |
| Live webcast: | www.columbialabs.com under "Events" in the Investor section |
A replay of the webcast will be available for 90 days on Columbia Laboratories website, www.columbialabs.com, under “Events” in the Investor section.
About Columbia Laboratories
Columbia Laboratories, Inc. is a U.S.-based international pharmaceutical company dedicated to the development and commercialization of women's health care and endocrinology products that use its novel bioadhesive drug delivery technology. Columbia markets Prochieve® 8% (progesterone gel) for progesterone supplementation as part of an Assisted Reproductive Technology treatment for infertile women with progesterone deficiency and Prochieve® 4% (progesterone gel) for the treatment of secondary amenorrhea. The Company also markets Striant® (testosterone buccal system) for the treatment of hypogonadism in men. The Company recently completed enrollment in a large-scale pivotal Phase III study to evaluate the possible utility of Prochieve® 8% (progesterone gel) in the prevention of preterm birth, for which there is currently no FDA-approved treatment. The Company’s additional research and development programs include a vaginally-administered lidocaine product to treat dysmenorrhea. For more information, please visit www.columbialabs.com.
Prochieve® and Striant® are registered trademarks of Columbia Laboratories, Inc.
###